Lewiecki E Michael, Lane Nancy E
New Mexico Clinical Research & Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, NM 87106, USA.
Nat Clin Pract Rheumatol. 2008 Dec;4(12):667-74. doi: 10.1038/ncprheum0928. Epub 2008 Oct 21.
Bone mineral density (BMD) testing is used to diagnose osteoporosis, assess fracture risk and monitor changes in BMD over time. A variety of devices and technologies are used to measure BMD or other surrogate markers of bone strength. Measurements obtained with these devices are often reported according to different proprietary standards, and the comparability of values obtained with different instruments is often poor. In addition, there is a high degree of variability in the skills of the technologists performing the tests and the clinicians interpreting the results. Heterogeneity in the guidelines for using BMD measurements together with poor-quality BMD testing and reporting can result in inappropriate clinical decisions, causing unnecessary worry and expense for the patient and possible harm due to unnecessary treatment or treatment being withheld. This Review describes and discusses the mistakes commonly made in BMD testing, and emphasizes the importance of maintaining high-quality standards in order to optimize patient management.
骨密度(BMD)检测用于诊断骨质疏松症、评估骨折风险以及监测骨密度随时间的变化。多种设备和技术用于测量骨密度或其他骨强度替代指标。使用这些设备获得的测量结果通常根据不同的专有标准进行报告,并且不同仪器获得的值的可比性通常较差。此外,进行检测的技术人员和解读结果的临床医生的技能存在很大差异。骨密度测量指南的异质性以及低质量的骨密度检测和报告可能导致不恰当的临床决策,给患者带来不必要的担忧和费用,并可能因不必要的治疗或延误治疗而造成伤害。本综述描述并讨论了骨密度检测中常见的错误,并强调了维持高质量标准以优化患者管理的重要性。